Elixirr International Acquires Kvadrant Consulting for £18 Million to Expand Nordic Presence

Elixirr International buys Kvadrant Consulting to fast-track Nordic expansion

Elixirr International has agreed to acquire Denmark-based Kvadrant Consulting for up to DKK154.8 million (£18.0 million). This is Elixirr’s first Nordic deal, its eighth since IPO in 2020, and its second since moving to the Main Market in July 2025. Management expects the acquisition to be immediately earnings-enhancing.

Kvadrant specialises in commercial transformation, go-to-market excellence and transaction services. It posted strong growth in recent years and brings a blue-chip, multinational client base that should open fresh cross-sell routes across Elixirr’s platform.

Kvadrant at a glance: growth, margins and clients

• Founder-led consultancy headquartered in Copenhagen.
• 25% revenue CAGR from FY22 to FY25.
• FY25 sales: DKK53.2 million (£6.2 million).
• Adjusted FY25 EBITDA: DKK19.7 million (£2.3 million), implying an EBITDA margin of roughly 37%.
• Core strengths: commercial transformation, go-to-market, and a fast-growing transaction services capability.
• Client sectors: healthcare, financial services, industrials and manufacturing. Named clients include Velux, Nordea and Scandic.
• Client feedback: due diligence benchmarking showed a 43% outperformance over peers (8.8/10 vs 6.1/10).

Founder and Managing Partner Thomas Børve-Jørgensen joins Elixirr as a Partner, remaining client-facing and focusing on growth across Denmark, the Nordics and continental Europe.

Why this deal matters for Elixirr shareholders

This acquisition lands Elixirr a credible hub in the Nordics – a high-growth, structurally attractive consulting market with strong access to Northern Europe and the DACH region. It also builds out Elixirr’s commercial strategy and go-to-market offering, while adding transaction services that sit neatly alongside the Group’s commercial M&A work.

Strategically, it should drive cross-selling in both directions: Kvadrant gets Elixirr’s global brand, client relationships and platform to scale, while Elixirr gets enhanced access to Private Equity and corporate M&A mandates via Kvadrant’s growing transaction services bench. Management says the deal will be earnings-enhancing from day one, which is a clear positive.

Deal structure, funding and key dates

Item	DKK	GBP	Notes
Maximum consideration	154.8 million	£18.0 million	Includes deferred, performance-based element
Initial cash	78.8 million	£9.1 million	Funded from operating cashflow and revolving credit facility
Share consideration	28.8 million	£3.3 million	415,213 new shares at £8.04 per share
Deferred consideration	Up to 47.3 million	Up to £5.5 million	Payable in cash or shares at Elixirr’s discretion, contingent on EBITDA margin and revenue targets through 31 Dec 2028
Lock-in	One-year lock-in from completion for sellers’ shares, then sale limitations for the following three years
Admission of new shares	Expected at 8.00 a.m. on 5 February 2026
Total shares in issue post-Admission	50,031,154 (the 415,213 new shares represent about 0.83% of the enlarged share capital)

A quick sense-check on valuation

On the disclosed FY25 figures, the maximum consideration equates to roughly 2.9x sales (DKK154.8m / DKK53.2m) and about 7.9x adjusted EBITDA (DKK154.8m / DKK19.7m). Those multiples are based on the full, performance-linked price; if earn-out targets are not met, the effective multiples would be lower. For a founder-led, growing consultancy with c.37% EBITDA margins and strong client endorsements, these numbers look reasonable.

The strategic upside: where value could come from

• Earnings-enhancing from day one – management expects immediate accretion, which supports the investment case.
• Nordic foothold – gives Elixirr same-day reach across the Nordics and into Northern Europe/DACH, accelerating the organic traction already built over the past 12 months.
• Transaction services uplift – bolsters Elixirr’s commercial M&A offering and improves access to PE and corporate mandates.
• Cross-sell potential – Kvadrant’s multinational clients (Velux, Nordea, Scandic) provide clear opportunities for wider Elixirr services, and vice versa.
• Quality marker – client benchmarking at 8.8/10 versus peers’ 6.1/10 suggests strong delivery and could aid win rates.
• Founders stay on – continuity matters. With Thomas Børve-Jørgensen joining as Partner, client relationships and momentum are retained.

Balanced view: what to watch and open questions

• Integration execution – it’s Elixirr’s first acquisition in the Nordics. Cultural fit looks good on paper, but seamless integration will be key to unlocking cross-sell.
• Earn-out structure – up to DKK47.3 million (£5.5 million) is contingent on performance through 2028. That should align incentives, but if paid in shares it could add further dilution (quantum not yet disclosed).
• Funding mix – the upfront cash draw was covered by operating cashflow and the revolving credit facility. Net debt or leverage metrics are not disclosed, so investors will want clarity at the next update.
• Share issuance – 415,213 new shares equate to roughly 0.83% of the enlarged share capital today. Future earn-out settlement in shares would raise that figure, at Elixirr’s discretion.
• Margin sustainability – Kvadrant’s c.37% adjusted EBITDA margin is attractive. Maintaining that while scaling under a larger platform is the test.

Timeline and near-term catalysts

• Admission of the 415,213 Consideration Shares is expected at 8.00 a.m. on 5 February 2026.
• Watch for commentary on early cross-sell wins, pipeline expansion in the Nordics and any update to Group guidance.
• Further detail on integration plans, revenue synergies and how the revolving credit facility is managed would be helpful.

My take

This looks like a strategically sensible bolt-on at a fair price for growth, margin and quality. It accelerates Elixirr’s push into a structurally attractive region, strengthens a high-demand capability set, and raises the firm’s relevance with PE and corporate clients. The immediate earnings-accretive claim is encouraging.

The usual caveats apply around integration and earn-out mechanics, and the final cost depends on delivery through 2028. But with founders staying on, solid client feedback and clear cross-sell logic, the risk-reward here leans positive. If management executes, this could be a tidy compounding deal for Elixirr’s shareholders.

Company contacts and further information

For enquiries, see Elixirr’s investor contacts page: https://www.elixirr.com/investors/investor-contacts